Search reports, ask a question, or jump to a page.
The problem
Intervention: Limited-eligibility nirsevimab program (monoclonal antibody against RSV) targeting high-risk infants, primarily those born prematurely
Who it was tested with: Infants aged less than 2 years residing in the Australian Capital Territory; 308 received nirsevimab with prematurity as the most common indication.
The same group is measured before the intervention and again afterwards, with a baseline and an endline and sometimes a midline. Change is visible, but other causes cannot be ruled out.
"This observational cohort study included all infants aged < 2 years residing in our jurisdiction with laboratory-confirmed RSV and/or receipt of an RSV monoclonal antibody between April 2022 and March 2025. Cases were followed for emergency department (ED) presentations and hospital admissions." The study tracks the same cohorts before and after program implementation, measuring changes in hospitalization patterns and clinical characteristics among high-risk infants to assess program effectiveness.
Observational design without randomized comparison group limits causal inference. No significant differences observed for Aboriginal and Torres Strait Islander infants, suggesting potential under-uptake or effectiveness differences in this population. Overall RSV incidence increased post-program, which may reflect seasonal or epidemiological trends rather than program impact.
Across countries and designs
8 studies · 17 countries
